Gemma Biotherapeutics ("GEMMABio"), a clinical‑stage, global, genetic medicines company, today announced the presentation of preclinical data supporting candidate declaration for GB703, a novel, ...

CNW/ - Families, friends, and supporters from coast to coast to coast are walking, running, and rolling this May, in support ...

EVRY, France--(BUSINESS WIRE)--Atamyo Therapeutics a clinical-stage biotechnology company focused on the development of new generation gene therapies targeting muscular dystrophies and ...

There is a new game changer for children with a certain form of muscular dystrophy. Now, a child who was destined to end up ...

Regenxbio said on Thursday that its experimental gene therapy to treat a muscle-wasting disorder met the main ​goal in a late-stage study. The Rockville, ‌Maryland-based company's shares, however, ...

Regenxbio said top-line results showed it met its primary endpoint in a Phase 3 study of its RGX-202 gene therapy for Duchenne Muscular Dystrophy. The trial met its primary endpoint with high ...

Regenxbio’s gene therapy for Duchenne muscular dystrophy has smashed the primary endpoint of its pivotal trial, securing a win for a biotech that has struggled in recent months under the weight of a ...

The first gene therapy for children with Duchenne muscular dystrophy has been approved by the U.S. Food and Drug Administration. The therapy can be used in 4- and 5-year-olds with the degenerative ...

Your muscles need continuous maintenance to stay strong and healthy. Duchenne muscular dystrophy (DMD) happens when there is a change in a person's genetic instructions that affects the production of ...

Regenxbio met its primary endpoint in a Phase 3 study of its Duchenne muscular dystrophy treatment, but it swung to a first-quarter loss as revenue plunged. Shares fell 20% to $8.06 in premarket ...